

Special Issue

Advances in the Diagnosis and Treatment of Kidney Disease

Message from the Guest Editors

The incidence of kidney disease is very high. Uremia, the renal endpoint of all kinds of kidney disease, impose a heavy burden on society. In recent years, many breakthroughs have been made in the pathogenesis of primary kidney disease, secondary kidney disease, and inherited kidney disease. Many new discoveries have been made in the search for molecular biomarkers of kidney disease. Clinical trials of new drugs for kidney disease have contributed greatly to the progress in treatment. The aim of this Special Issue is to provide a publishing platform for the discoveries and progress in all kinds of kidney diseases. Basic research focused on the pathogenesis, clinical trials of new drugs, and reviews of the diagnosis and treatment of kidney diseases are welcome for submission. We hope that this Special Issue will shed light on the pathogenesis of kidney disease and promote progress in the diagnosis and treatment of kidney diseases. We invite original research, reviews, etc., that focus on the latest research progress in the diagnosis and treatment of kidney diseases.

Guest Editors

Dr. Shen-ju Gou

West China Hospital of Sichuan University, Chengdu, China

Dr. Liang Ma

Division of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu 332001, China

Deadline for manuscript submissions

closed (10 August 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/163347

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

[jpm](https://mdpi.com/journal/)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).